Juvenescence, which aims to increase its lifespan to 150 years shortly, raised $ 100 million in its latest fundraising campaign.
Founded in 2016, Juvenescence is the company that is creating an “ecosystem of longevity”. With world-renowned scientists, pharmacologists, machine learning experts and capable managers able to move confidently in this rapidly expanding biotech sector.
The latest press release from the company announces financing of 10 million dollars from its founders and another 10 million each for 4 other investors. These include Grok Ventures, Mike Cannon-Brookes' investment firm, and the private fund IPGL. The total raised by Juvenescence in the last 18 months is therefore $165 million, a figure that shows the growth in interest in medical therapies aimed at longevity.
“Juvenescence has raised more funds than other similar companies, which is good news for longevity. It's a reward for the capabilities of our team. It makes us believe even more in the opportunities we are testing in collaboration with scientists, entrepreneurs and research institutes,” says Jim mellon, one of the founders of Juvenescence.
“We have brought together a group of amazing experts from around the world for our common mission to extend human life. As longevity becomes a known theme, we expect investor interest to increase. The next phase will be to list Juvenescence on the stock exchange to further accelerate its development.”
12 apostles of longevism: they will become 4 (or more) evangelists
The funds raised will be used to advance the various anti-aging programs, 12 of which are undergoing clinical trials. Of these, at least 4 will be on the market between 5 and 7 years from 2019.
Among these, many bring products that slow down cellular aging. Others reverse neurodegenerative processes or destroy senescent cells. Still others replace exhausted organs and edit patients' genes.
“The last six months have been really exciting for Juvenescence,” says the CEO Dr. Greg Bailey. “Extraordinary medical and IT professionals have joined the team and will help us bring our therapies to the public. This new injection of funds will give us the capital necessary to fully develop our first solutions."
Il longevism he gets more and more interest and money. The global anti-aging market is estimated at around 110 billion dollars.
